• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Food>Food And Drug Administration

Food And Drug Administration

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone)

    Shire Comments on Press Release from NPS Pharma Regarding FDA Approval of NATPARA® (parathyroid hormone)

  2. Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome

    Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome

  3. Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted

    Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted

  4. Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

    Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

  5. Roche receives FDA clearance for next generation cobas MRSA/SA Test

    Roche receives FDA clearance for next generation cobas MRSA/SA Test

  6. FDA Rejects Antares' Application for Generic Migraine Drug

    FDA Rejects Antares' Application for Generic Migraine Drug

  7. NPS Hormone Drug Gets FDA Approval

    NPS Hormone Drug Gets FDA Approval

  8. Teva's generic version of AstraZeneca's Nexium gets FDA approval

    Teva's generic version of AstraZeneca's Nexium gets FDA approval

  9. FDA Grants Priority Review for Sanofi and Regeneron's Drug

    FDA Grants Priority Review for Sanofi and Regeneron's Drug

  10. Nevro Receives Approvable Letter from U.S. Food and Drug Administration for Senza® Spinal Cord Stimulation System

    Nevro Receives Approvable Letter from U.S. Food and Drug Administration for Senza® Spinal Cord Stimulation System

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.